Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study.
Hiroki WakabayashiNobuto NagaoHitoshi InadaYosuke NishiokaMasahiro HasegawaKusuki NishiokaAkihiro SudoPublished in: Drugs in R&D (2021)
Administration of GLM-SC at 4-week and 8-week intervals after switching from TNF inhibitors showed sustained long-term efficacy and acceptable safety in RA patients with low disease activity.
Keyphrases
- disease activity
- rheumatoid arthritis
- ankylosing spondylitis
- rheumatoid arthritis patients
- systemic lupus erythematosus
- juvenile idiopathic arthritis
- interstitial lung disease
- randomized controlled trial
- systematic review
- electronic health record
- ultrasound guided
- clinical trial
- placebo controlled
- deep learning
- study protocol
- ulcerative colitis